000154259 001__ 154259
000154259 005__ 20240411115841.0
000154259 0247_ $$2doi$$a10.1186/s13195-020-00702-6
000154259 0247_ $$2pmid$$apmid:33076977
000154259 0247_ $$2pmc$$apmc:PMC7574434
000154259 0247_ $$2altmetric$$aaltmetric:92732487
000154259 037__ $$aDZNE-2021-00113
000154259 041__ $$aEnglish
000154259 082__ $$a610
000154259 1001_ $$0P:(DE-HGF)0$$aRubinski, Anna$$b0
000154259 245__ $$aFDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels.
000154259 260__ $$aLondon$$bBioMed Central$$c2020
000154259 3367_ $$2DRIVER$$aarticle
000154259 3367_ $$2DataCite$$aOutput Types/Journal article
000154259 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1712755948_11348
000154259 3367_ $$2BibTeX$$aARTICLE
000154259 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154259 3367_ $$00$$2EndNote$$aJournal Article
000154259 500__ $$aISSN 1758-9193 not unique: **3 hits**.
000154259 520__ $$aFDG-PET hypermetabolism can be observed in mild cognitive impairment (MCI), but the link to primary pathologies of Alzheimer's diseases (AD) including amyloid and tau is unclear.Using voxel-based regression, we assessed local interactions between amyloid- and tau-PET on spatially matched FDG-PET in 72 MCI patients. Control groups included cerebrospinal fluid biomarker characterized cognitively normal (CN, n = 70) and AD dementia subjects (n = 95).In MCI, significant amyloid-PET by tau-PET interactions were found in frontal, lateral temporal, and posterior parietal regions, where higher local tau-PET was associated with higher spatially corresponding FDG-PET at low levels of local amyloid-PET. FDG-PET in brain regions with a significant local amyloid- by tau-PET interaction was higher compared to that in CN and AD dementia and associated with lower episodic memory.Higher tau-PET in the presence of low amyloid-PET is associated with abnormally increased glucose metabolism that is accompanied by episodic memory impairment.
000154259 536__ $$0G:(DE-HGF)POF3-341$$a341 - Molecular Signaling (POF3-341)$$cPOF3-341$$fPOF III$$x0
000154259 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000154259 650_7 $$2Other$$aAmyloid-PET
000154259 650_7 $$2Other$$aFDG-PET
000154259 650_7 $$2Other$$aHyperactivation
000154259 650_7 $$2Other$$aHypermetabolism
000154259 650_7 $$2Other$$aMild cognitive impairment
000154259 650_7 $$2Other$$aTau-PET
000154259 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000154259 650_2 $$2MeSH$$aAmyloid
000154259 650_2 $$2MeSH$$aAmyloid beta-Peptides
000154259 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000154259 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000154259 650_2 $$2MeSH$$aHumans
000154259 650_2 $$2MeSH$$aPositron-Emission Tomography
000154259 650_2 $$2MeSH$$atau Proteins
000154259 7001_ $$aFranzmeier, Nicolai$$b1
000154259 7001_ $$aNeitzel, Julia$$b2
000154259 7001_ $$0P:(DE-2719)9000543$$aEwers, Michael$$b3$$eCorresponding author$$udzne
000154259 7001_ $$aInitiative, Alzheimer’s Disease Neuroimaging$$b4$$eCollaboration Author
000154259 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-020-00702-6$$gVol. 12, no. 1, p. 133$$n1$$p133$$tAlzheimer's research & therapy$$v12$$x1758-9193$$y2020
000154259 8564_ $$uhttps://alzres.biomedcentral.com/articles/10.1186/s13195-020-00702-6
000154259 8564_ $$uhttps://pub.dzne.de/record/154259/files/DZNE-2021-00113.pdf$$yOpenAccess
000154259 8564_ $$uhttps://pub.dzne.de/record/154259/files/DZNE-2021-00113.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000154259 909CO $$ooai:pub.dzne.de:154259$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000154259 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000543$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000154259 9131_ $$0G:(DE-HGF)POF3-341$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vMolecular Signaling$$x0
000154259 9132_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000154259 9141_ $$y2020
000154259 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000154259 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-27
000154259 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:57Z
000154259 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-27
000154259 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:57Z
000154259 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000154259 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-27
000154259 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-27
000154259 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000154259 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-27
000154259 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x0
000154259 980__ $$ajournal
000154259 980__ $$aVDB
000154259 980__ $$aUNRESTRICTED
000154259 980__ $$aI:(DE-2719)1110008
000154259 9801_ $$aFullTexts